. 2017 Jul 13;39(4):350–355. doi: 10.1097/FTD.0000000000000393
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
TABLE 1.
EMA and FDA Approved DMTs for Multiple Sclerosis
